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Abstract 
Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in 
a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by 
nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets 
that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy. 
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Targeted Therapy in Triple Negative 
Breast Cancer (TNBC) 
In 2010, 209,060 patients are expected to be di-
agnosed with breast cancer in the United States.1 At 
least 20% of breast cancers are characterized by  tri-
ple-negative  receptor  status  (negative  for  estrogen 
receptor  [ER],  progesterone  receptor  [PR],  and 
HER2).2  Triple-negative  breast  cancer  (TNBC)  is 
highly proliferative and sensitive to systemic chemo-
therapies. However, despite its relative sensitivity to 
chemotherapy, patient outcomes are poor compared 
with other subtypes of breast cancer (HER2+ or ER+). 
The  cause  of  death  of  patients  with  TNBC  is  often 
recurrence (30–40% of TNBC cases), which presents as 
distant metastasis. This means that chemosensitivity 
of TNBC does not reflect whether the cancer will me-
tastasize.  Therefore,  the  mechanism  of  metastasis 
needs  to  be  studied  separately  from  that  of  tumor-
igenicity. 
TNBC is the only major type of breast cancer for 
which no specific FDA-approved targeted therapy is 
available to improve patient outcomes; it is resistant 
to targeted therapies such as hormonal therapy and 
HER2-targeting therapy. A PARP inhibitor is under 
development, but it is not yet an established standard 
therapy.  Our  preliminary  data  show  that  erlotinib 
inhibits TNBC in a xenograft model, a promising re-
sult. However, inhibition of metastasis by erlotinib is 
accompanied by nonspecific effects because erlotinib 
can inhibit other kinases; thus, more direct targets that 
regulate  TNBC  metastasis  need  to  be  identified  to 
improve its therapeutic efficacy.  
EGFR overexpression in TNBC 
EGFR is known to be overexpressed in TNBC.
3-5 
The question remains whether EGFR is a valid target 
when  many  of  the  Phase  II  study  of  EGFR  tyro-
sine-kinase inhibitor in metastatic breast cancer has at 
most  5%  response  rate.  However,  At  the  European 
Society  for  Medical  Oncology  meeting  in  October 
2010, a major breakthrough in EGFR-targeted therapy 
was reported.
6 In this randomized phase II study, 173 
patients with metastatic TNBC were randomized to 
receive either cetuximab, an anti-EGFR antibody, plus 
up to six 3-week cycles of cisplatin (N=115) or cispla-
tin alone (N=58). An overall response rate of 20% was 
seen in patients who received the cetuximab/cisplatin 
combination, compared with a response rate of 10.3% 
in the cisplatin-alone arm. Adding cetuximab to cis-
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platin doubled the progression-free survival duration 
from 1.5 to 3.7 months (HR 0.675, P = 0.032). These 
exciting  clinical  data  suggest  that  EGFR  is  an  im-
portant target in TNBC.
6  
EGFR inhibitor induced a change from 
mesenchymal to epithelial phenotype in 
TNBC cells.  
Human TNBC may have characteristics of epi-
thelial-mesenchymal  transition  (EMT).4,  5  EMT  is  an 
essential  developmental  process  by  which  cells  of 
epithelial  origin  lose  epithelial  characteristics  and 
acquire  a  mesenchymal  phenotype  with  fibro-
blast-like  morphology,  cytoskeleton  reorganization, 
increased motility, invasiveness, and metastatic capa-
bility.7, 8 EMT is characterized by loss of epithelial cell 
junction proteins (e.g., E-cadherin and cytokeratins) 
and gain of mesenchymal markers (e.g., vimentin and 
fibronectin).7,  8  It  has  been  proposed  that  EMT-like 
processes allow tumor cells to disassemble and  mi-
grate to tissue or organ sites distant from the primary 
tumor (metastasis).7, 8 It has become increasingly clear 
that EMT may play a major role in invasion and me-
tastasis of TNBC.3-5  
We  have  previously  shown  that  epidermal 
growth factor stimulates EGFR-expressing TNBC cells 
such  as  SUM149,  MDA-MB-468,  and  BT-20  and  in-
duces  upregulation  of  phosphorylation  of  ERK 
and/or Akt. Further, when these cells are treated with 
the  EGFR  tyrosine  kinase  inhibitor  (TKI)  erlotinib, 
ERK and/or Akt phosphorylation can be downregu-
lated. These data suggest that the EGFR pathway is 
intact in these cells.9, 10 
To further elucidate EGFR pathway activity in 
TNBC, we examined whether TNBC cells (SUM149) 
exhibited  epithelial  or  mesenchymal  phenotypes. 
SUM149 cells were plated using a three-dimensional 
(3D) culture system. The 3D culture was performed 
with 2% Matrigel in F12 medium containing 5% FBS. 
Matrigel is a gelatinous protein mixture secreted by 
mouse tumor cells, which resembles the complex ex-
tracellular environment found in many tissues. This 
3D  culture  system  can  be  used  to  assess  cell  inva-
siveness and motility, which reflect part of the epithe-
lial-to-mesenchymal morphological process due to the 
rapid  formation  of  projections  and  filopodia.  Such 
projections  or  filopodia  also  may  strongly  correlate 
with metastatic potential.
11-14  
In a two-dimensional (2D) culture system, using 
standard culture plates with F12 medium containing 
5% FBS, SUM149 cells showed an epithelial pheno-
type characterized by the  localization of E-cadherin 
and β-catenin at the sites of cell-cell contact (data not 
shown).  However,  in  a  3D-culture  system,  SUM149 
cells  rapidly  formed  projections  or  filopodia  and 
changed to a mesenchymal-like phenotype (Fig. 1A) 
within 24 hours.  
In 3D culture, SUM149 cells with projections ex-
hibited reduced E-cadherin expression and increased 
vimentin expression compared with SUM149 cells in 
2D culture. Also, β-catenin accumulated at the cyto-
plasm in 3D culture (Fig. 1B). 
However, when these cells were treated with the 
EGFR-TKI erlotinib, the mesenchymal cell phenotype 
changed  back  to  epithelial-like  in  the  3D  system, 
E-cadherin  was  upregulated,  vimentin  was  down-
regulated,  and  β-catenin  localized  to  the  cell  mem-
brane (Fig. 1B). Interestingly, the erlotinib concentra-
tion that inhibited the mesenchymal phenotype (0.1 
M) did not have a cytotoxic effect and was one log 
lower than the concentration that inhibited prolifera-
tion (1 M).15  
EGFR tyrosine kinase inhibitor erlotinib 
inhibited tumor growth and metastasis in a 
SUM149 xenograft mouse model.  
After observing that erlotinib reversed the mes-
enchymal phenotype of SUM149 TNBC cells in vitro, 
we hypothesized that erlotinib inhibits tumor growth 
and metastasis in a SUM149 TNBC xenograft model.
15 
To address this hypothesis, we generated a SUM149 
xenograft model by implanting luciferase-expressing 
SUM149  (SUM149-luc)  cells  into  the  mammary  fat 
pads  (mfp)  of  athymic  nude  mice.  SUM149  tumors 
were readily apparent in the mfp after 14 d and grew 
rapidly. Beginning 3 w after tumor cell implantation, 
the mice were treated with erlotinib or a vehicle con-
trol  administered  by  oral  gavage  daily  for  4  w.  To 
identify the optimal doses that inhibit tumor growth 
and/or metastasis, we used three different doses of 
erlotinib  (25,  50,  or  100  mg  per  kilogram  of  body 
weight).  The  doses  of  50  and  100  mg/kg/d  were 
chosen based on previous studies of antitumor activ-
ity of erlotinib.
16, 17 The dose of 25 mg/kg/day was 
chosen because of its known subtherapeutic effect. 
The higher doses (50 and 100 mg/kg) of erlotinib 
showed  significant  tumor-growth  inhibition  in  the 
SUM149 xenograft model  (Fig. 2A). On day 49, the 
mean tumor-growth inhibition rates compared with 
the control group were 84% in the 50-mg/kg group (P 
<  0.0001)  and  103%  in  the  100-mg/kg  group  (P  < 
0.0001).  Some  tumor  growth  inhibition  (43%)  was 
observed in the 25-mg/kg group, but this inhibition 
was not significant compared with the control group 
(P  =  0.06)  (Fig.  2A).  To  evaluate  the  anti-metastatic 




animal study, we collected lung tissues from the mice 
and then performed ex vivo luciferase imaging to de-
tect spontaneous lung metastases (Fig. 2B). The meta-
static tumors in bioluminescence-positive lung tissues 
were  further  confirmed  by  hematoxylin  and  eosin 
staining  (Fig.  2C).  Bioluminescence-positive  lungs, 
indicating  the  presence  of  metastatic  tumors,  were 
detected in 3 of 7 mice (43%) in the control  group. 
However,  no  bioluminescence-positive  lungs  were 
detected in mice in the three erlotinib-treated groups, 
indicating that erlotinib inhibited lung metastasis of 
TNBC (P = 0.04) (Fig. 2D).
15  
In  immunohistochemical  analysis,  erlotinib  in-
creased  the  expression  of  the  epithelial  marker 
E-cadherin  and  lowered  the  expression  of  the  mes-
enchymal  marker  vimentin  in  all  treated  tumors 
compared  with  control  tumors  (Fig.  2E).  In  conclu-
sion, inhibition of lung metastasis and reversal from a 
mesenchymal  to  an  epithelial  phenotype  were  ob-
served  even  in  the  low-dose  condition  (25-mg/kg 
erlotinib), whereas at that dose primary tumor growth 
was similar between the treated and control groups.
15 
These findings suggest that EMT modulation by tar-





Fig. 1. EGFR inhibitor induced a change from mesenchymal to epithelial phenotype in TNBC cells. A, SUM149 
TNBC cells were grown (3D culture) in the presence of 0 or 0.1 M erlotinib, an EGFR tyrosine kinase inhibitor. Er-
lotinib (0.1 M) inhibited the formation of projections in 3D models at 24 h. In 2D culture, no projections formed. B, 
Immunostaining performed after 24 h of treatment with erlotinib shows upregulation of epithelial marker E-cadherin, 
cell membrane localization of -catenin, and inhibition of mesenchymal marker vimentin. The figure is referenced 
from Clin Cancer Res. 2009;15(21):6639-48. 
 





Fig. 2. Erlotinib inhibited tumor growth and metastasis in a SUM149 xenograft model. A, Tumor volumes in 4 
groups of mice (vehicle, 25, 50, and 100 mg/kg erlotinib) were measured weekly. Each data point represents the 
mean tumor volume of 7 mice per group; bars, SD. B, Findings on ex vivo imaging of lung tissues to detect metastatic 
tumors in a control (vehicle) mouse and a 25-mg/kg erlotinib-treated mouse. C, Hematoxylin and eosin staining of a 
lung tissue section from a control mouse at the endpoint of the study showed 2 small deposits of metastatic tumors 
(arrowheads) in the alveolar septae. D, The incidence of lung metastasis in the 4 groups of mice. E, Immunohisto-
chemical analysis of p-EGFR, p-ERK, E-cadherin, and vimentin in tumor tissues of SUM149 xenografts. The figure is 
referenced from Clin Cancer Res. 2009;15(21):6639-48. 
 
Summary 
The above results support a concept that metas-
tasis and tumorigenicity should be considered sepa-
rately and justify the need to study the role of EGFR in 
TNBC metastasis.  
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